Importantly, in pediatric gliomas, gene fusions involving anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK2) and MET define a distinct, hemispheric high-grade subgroup with intermediate prognosis [51]. The gene discussed is ROS1; the disease is central nervous system cancer.